CLINUVEL PHARMAC.ADRS1
Research CLINUVEL PHARMAC.ADRS1 (UR9A) on Bullrun: market cap EUR 252.14M, P/E 12.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerUR9A
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 252.14M
- P/E12.8
- Financial periodFY2025
- RevenueAUD 95.02M
- Revenue growth7.8%
- Net incomeAUD 36.17M
- Free cash flowAUD 40.80M
- Gross margin83.3%
Valuation Snapshot
latest market cap is EUR 252.14M; P/E is 12.8.
Peer valuation comparison
Latest P/E is 12.82x versus a Healthcare sector median of 21.69x (40.9% below).
Latest P/E is 12.82x versus a Australia median of 14.68x (12.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 95.02M | AUD 36.17M | AUD 40.80M | 83.3% | 0.72 | AUD 224.11M | AUD 528.53K | AUD 240.81M |
| FY2024 | AUD 88.18M | AUD 35.64M | AUD 31.48M | 88.6% | 0.7 | AUD 183.87M | AUD 879.78K | AUD 203.01M |
| FY2023 | AUD 78.32M | AUD 30.60M | AUD 35.88M | 88.8% | 0.59 | AUD 156.81M | AUD 999.87K | AUD 164.63M |
| FY2022 | AUD 65.72M | AUD 20.88M | AUD 39.44M | 84.0% | 0.4 | AUD 121.51M | AUD 1.26M | AUD 125.56M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-05 | EUR 252.14M | 12.8 | 0.7% | 0.03 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.03 EUR.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.03 AUD |
| FY2024 | 0.03 AUD |
| FY2023 | 0.03 AUD |
| FY2022 | 0.02 AUD |
About CLINUVEL PHARMAC.ADRS1
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CLINUVEL PHARMAC.ADRS1's market cap?
CLINUVEL PHARMAC.ADRS1's market capitalization is EUR 252.14M.
What is CLINUVEL PHARMAC.ADRS1's P/E ratio?
CLINUVEL PHARMAC.ADRS1's price-to-earnings (P/E) ratio is 12.8.
What does CLINUVEL PHARMAC.ADRS1 do?
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.